全身动态PET微剂量数据建模预测格列本脲人体全身药代动力学
本研究利用16名健康受试者注射[11C]格列本脲后的全身动态PET数据,采用非线性混合效应模型构建药代动力学模型,其中10名受试者在利福平给药后再次进行PET采集。最终模型包含七个隔室,利福平使肝脏分布降低261%,估计的中心分布容积(3.6 L)和消除速率(0.8 h-1)与格列本脲已知药代动力学一致。
要点
- 基于[11C]格列本脲微剂量PET数据构建七隔室药代动力学模型。
- 利福平使肝脏分布降低261%,提示药物相互作用可能抑制肝摄取。
- 估计的中心分布容积3.6 L和消除速率0.8 h-1与已知格列本脲药代动力学一致。
核心结论
- 基于全身动态PET微剂量数据构建的药代动力学模型可描述格列本脲的全身分布,且估计参数与标准药代动力学研究一致。
研究设计与样本
- 本研究分析了16名健康受试者注射[11C]格列本脲后40分钟内的全身动态PET数据,使用非线性混合效应模型进行建模。
- 其中10名受试者在利福平给药后进行了第二次PET采集,以评估药物相互作用对肝脏摄取的影响。
主要发现
- 最终模型包含七个隔室,肝脏和肾脏各有两个隔室以解释组织内交换。
- 利福平使肝脏分布降低261%。
- 估计的中心分布容积为3.6 L,消除速率为0.8 h-1。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Whole-body dynamic (WB4D) positron emission tomography (PET) imaging data using radiolabeled analogs of drugs are mostly analyzed using descriptive approaches, with no relationship to traditional pharmacokinetic studies based on blood sampling. Here, we build a pharmacokinetic (PK) model from WB4D PET data obtained using a microdose of radiolabeled glyburide ([11C]glyburide) in humans, aiming to describe the biodistribution of this drug and compare estimated pharmacokinetic parameters with the parameters obtained in standard PK studies. METHODS: The present work analyzes data acquired over 40 min after injection of [11C]glyburide in 16 healthy subjects using non-linear mixed-effect models (NLMEM). In 10 subjects, a second PET acquisition was performed after rifampicin administration, which may cause a drug-drug interaction and inhibit the liver uptake transport of glyburide. Arterial blood, liver, kidneys, pancreas, and spleen kinetics were modeled using NLMEM. The model-building strategy involved selecting the structural model using baseline [11C]glyburide PET data and then selecting the covariate model (rifampicin, age, and gender) and refining the structure of the interindividual variability model using both administration periods. Model selection was based on the corrected Bayesian information criterion and implemented in Monolix software. RESULTS: The final model included seven compartments, with two compartments each for the Liver and kidneys to account for within-tissue exchanges. Rifampicin decreased the Liver distribution by 261%. DISCUSSION: The estimated central volume of distribution (V = 3.6 L) and elimination rate (k = 0.8 h-1) were consistent with the known pharmacokinetics of glyburide, which is a promising first step in leveraging microdose data to study the WB4D biodistribution. REGISTRATION: EudraCT identifier no. 2017-001703-69.
引用
- Comin L, Marie S, Ursino M, et al. Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in Humans. Clin Pharmacokinet. 2025. PMID: 40960559. doi:10.1007/s40262-025-01562-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。